This site provides INTERCEPT product information for International audiences Select your region
The Swiss Red Cross Humanitarian Foundation has awarded a grant of 2 million Swiss Francs to Cerus, the University Hospital of Basel, and the Swiss Transfusion SRC to complete the necessary clinical studies to develop a whole blood pathogen inactivation system for use in Africa. In many African countries, whole blood transfusions remain common, requiring the development of a robust whole blood pathogen inactivation system optimized for use within the limited infrastructure of local blood banks and hospitals. Such system has been developed, consisting of a process that is easy to use in remote settings, without the need for electricity.
“Blood safety is a significant health concern in Africa, where a number of endemic pathogens may be present in donated blood,” said Dr. Rudolf Schwabe, chief executive officer of Swiss Transfusion SRC. “We have an obligation to bring this technology to Africa and other regions where it has the potential to vastly improve blood safety."
Want to stay updated on the latest pathogen inactivation news?
You can receive our highlights by subscribing to our newsletter.
Do you have questions about the INTERCEPT™ Blood System, blood safety or blood transfusions? The INTERCEPT team has plenty of knowledge and expertise.
The information on this site is not country-specific, and may contain information that is outside the approved indications for the country in which you are located.
Use of INTERCEPT Plasma or Platelets is contraindicated in patients with a history or allergic response to amotosalen or psoralens. Consult instructions for use for indications, contraindications, warnings, and precautions.
Cerus, INTERCEPT and the Cerus logo are trademarks of Cerus Corporation.
© 2023 Cerus Corporation. All Rights Reserved. MKT-EN 00157 v43.0